Skip to navigation Skip to content

Myelofibrosis Program in Pharmaceutical Benefits Scheme (PBS) 012-18051126

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised ruxolitinib for patients with myelofibrosis (MF).

Myelofibrosis and listing dates

Myelofibrosis (MF) is a serious bone marrow disorder that disrupts the body's normal production of blood cells.

Listing dates are:

  • ruxolitinib - February 2016

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.

The Resources page contains links to application forms, contact details, item and restriction codes, the PBS schedule and the Services Australia website.

Tier 0 technical support - self-sufficiency

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing Written Authority requests

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs